ストックスクリーナーアプリを入手
1.13
0.00%
0.00
アフターアワーズ：
1.13
前日終値:
$1.13
開ける：
$1.12
24時間の取引高:
161.69K
Relative Volume:
0.45
時価総額：
$95.82M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+0.90%
1か月 パフォーマンス:
-15.67%
6か月 パフォーマンス:
-23.13%
1年 パフォーマンス:
+5.61%
1日の値動き範囲:
$1.10
$1.1797
1週間の範囲:
$0.9384
$1.20
52週間の値動き範囲:
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
CTOR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
1.13 | 95.82M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-23 | アップグレード | Maxim Group | Hold → Buy |
| 2024-11-27 | 開始されました | Maxim Group | Buy |
Citius Oncology Inc (CTOR) 最新ニュース
Citius Oncology closes $18 million in offerings to support LYMPHIR launch - Investing.com Nigeria
Citius Oncology Raises $18M Through Direct Offering - TipRanks
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Benzinga
Citius Oncology raises $18 million to support cancer therapy launch By Investing.com - Investing.com Canada
Citius Oncology added to the Russell Microcap Index - MSN
Citius Oncology shares sink after announcing $18M fundraising deal - MSN
Citius Oncology raises $18 million to support cancer therapy launch - Investing.com
Citius Oncology stock tumbles after $18M capital raise By Investing.com - Investing.com South Africa
Citius Oncology stock tumbles after $18M capital raise - Investing.com
Citius Oncology announces $18 million concurrent registered direct offering and private placement priced at-the-market under Nasdaq rules - marketscreener.com
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - PR Newswire
Citius Oncology, Inc. announced that it expects to receive $16.6 million in funding - marketscreener.com
What drives Citius Oncology Inc stock priceStock Price Divergence & Calculate Profit Targets With AI Accuracy - earlytimes.in
Is Citius Oncology Inc a good long term investmentLow Beta Stocks & Free Rapid Profit Acceleration - earlytimes.in
Citius Oncology Launches Lymphir In US For Skin Cancer - MSN
Citius Oncology expands lymphir distribution to Turkey, Middle East By Investing.com - Investing.com Nigeria
Is Citius Oncology Inc. stock a top pick in earnings season2025 Dividend Review & Weekly Top Gainers Alerts - Newser
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - The Malaysian Reserve
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Midd - GuruFocus
Citius Oncology expands lymphir distribution to Turkey, Middle East - Investing.com
Citius Oncology expands Lymphir distribution to Turkey and Middle East countries - marketscreener.com
Citius Oncology Expands Lymphir Distribution To Turkey And Middle East Countries - TradingView
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim – Company AnnouncementFT.com - Financial Times
What Wall Street predicts for Citius Oncology Inc. stock priceStop Loss & Growth Focused Stock Pick Reports - Newser
Citius Oncology launches Lymphir treatment for rare lymphoma - NJBIZ
Citius Oncology enters distribution services agreement with Cardinal Health - MSN
Does Citius Oncology Inc (CTOR) offer a good opportunity for investors? - Setenews
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - marketscreener.com
Citius Oncology (CTOR) Stock Analysis Report | Financials & Insights - Benzinga
Citius launches Lymphir in USA for relapsed or refractory CTCL - The Pharma Letter
Citius Oncology Launches LYMPHIR, The First CTCL Systemic Therapy In Over 7 Years - Nasdaq
Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma - MSN
Will Citius Oncology Inc. stock continue upward momentumJuly 2025 Market Mood & Target Return Focused Picks - Newser
Citius Oncology Announces U.S. Commercial Launch of LYMPHIRtm, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - Lelezard
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan
How Citius Oncology Inc. stock performs in weak economyWeekly Earnings Recap & Low Risk High Reward Ideas - Newser
Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma - TipRanks
Citius Oncology, Inc. Announces U.S. Launch of LYMPHIR for CTCL - TradingView
Citius Oncology : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com
Citius Oncology announces U.S. commercial launch of Lymphir for cutaneous T-cell lymphoma - marketscreener.com
Citius Oncology stock soars after commercial launch of LYMPHIR therapy By Investing.com - Investing.com South Africa
Citius Oncology stock soars after commercial launch of LYMPHIR therapy - Investing.com
Citius Oncology rises after U.S. launch of Lymphir as a cancer treatment - Seeking Alpha
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a - GuruFocus
Citius Oncology Launches Cancer Drug Lymphir in the US - marketscreener.com
Citius Oncology launches lymphir for cutaneous T-cell lymphoma By Investing.com - Investing.com South Africa
Citius Oncology launches lymphir for cutaneous T-cell lymphoma - Investing.com
Citius Oncology Launches Lymphir In US For Skin Cancer — Retail Traders Eye Major Upside - Stocktwits
Citius Oncology Inc (CTOR) 財務データ
Citius Oncology Inc (CTOR) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.48%
0.09%
大文字化:
|
ボリューム (24 時間):